Jump to content

RAD - RADIOPHARM THERANOSTICS LIMITED


nipper
 Share

Recommended Posts

Radiopharm Theranostics Limited (RAD) is a clinical stage radiotherapeutics company targeting some of the largest markets in cancer.

The Company has a pipeline of four licenced platform technologies, with diagnostic and therapeutic applications in both preclinical and clinical stages of development, from some of the world’s leading universities and institutes such as Imperial College London and Memorial Sloan Kettering.

The assets span all size molecules comprising peptides, fatty acids and antibody targets and are as follows:

(a) Nano-mAbs technology
Nano-mAbs technology platform is the invention of Dr Hong Hoi Ting. Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb), that can be labelled with radioisotopes in order to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Phase 1 imaging in 33 patients (in Shanghai and Germany) is complete, with results indicating the potential for use as whole-body assessment and treatment of HER-2+ cancers with different medical radioisotopes. Therapeutic compassionate use study in HER-2+ breast cancer therapy is anticipated to commence 2HCY2021.

(b) Pivalate
Pivalate is an 18F-FPIA radiotracer and is the invention of Professor Eric Aboagye of Imperial College London. The technology is based on a short chain carbohydrate which utilises the early steps of fatty acid oxidation and is very stable. In comparison to the clinical standard in PET imaging, 18F-FDG in prostate and brain cancers, Pivalate showed superior imaging performance and was equally good for two breast cancer models. Phase 1 diagnostic trial in high and low grade glioma is complete. Phase 2 diagnostic renal, glioma, cerebral metastases and other solid tumours also recruiting or underway.

(c) AVβ6 Integrin
AVβ6 is the invention of internationally regarded integrin expert, Professor Johannes Notni, formerly at the Technical University of Munich. AVβ6 is a strong selective ligand for a cell surface protein called αvβ6-integrin. As such, it can accumulate in tissue areas characterised by high αvβ6-integrin level. There is compelling evidence that αvβ6-integrin is over expressed in many of the most challenging cancers such as pancreatic, cervical, head & neck and certain lung cancers. AVβ6 offers noteworthy performance for radiolabelling with 68Ga and is a promising candidate for early detection of the above-mentioned conditions by PET imaging. A diagnostic compassionate use study in ongoing in Germany in pancreatic and head & neck cancer with ten patients to date.

(d) PSA-mAb
PSA-mAb is the invention of Professor David Ulmert of UCLA and Essen University. PSA-mAb is a humanized monoclonal antibody, capable of targeting free human prostate kallikrein (or prostate specific antigen (PSA)) in prostate cancer cells. The antibody platform enables a theranostic approach for prostate cancer. Attachment to 225Ac results in curative treatment by sustained tumour regression and a significant increase in median survival time. PSA-mAb is at pre clinical stage.

 

Listing date 25 November 2021 11:00 AM AEDT ##
Company contact details https://radiopharmtheranostics.com/
Ph: +61 (0) 3 9824 5254
Principal Activities Radiopharm is a clinical stage radiotherapeutics company targeting some of the largest markets in cancer.
   
Issue Price AUD 0.60
Issue Type Fully Paid Units Stapled Securities
Security code RAD
Capital to be Raised $50,000,000
Expected offer close date 05 November 2021
Underwriter Not underwritten. Bell Potter Securities Limited and Baker Young Limited (Joint Lead Managers)
Link to comment
Share on other sites

and slip slip sliding away. On Day One, RAD opened below IPO at 47c and basically never got anywhere, closing at 40c.

The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share

×
×
  • Create New...